Get Premium to unlock powerful stock data
NAS:PHAT (USA)  
Phathom Pharmaceuticals Inc logo

Phathom Pharmaceuticals Inc

$ 8.20 -0.84 (-9.29%) 08:08 PM EST
P/E:
At Loss
P/B:
8.59
Market Cap:
$ 320.39M
Enterprise V:
$ 307.73M
Volume:
189.80K
Avg Vol (2M):
363.22K
Volume:
189.80K
Market Cap $:
320.39M
PE Ratio:
At Loss
Avg Vol (2-Month):
363.22K
Enterprise Value $:
307.73M
PB Ratio:
8.59
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Phathom Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Name Current Vs Industry Vs History
Cash-To-Debt 1.49
Equity-to-Asset 0.26
Debt-to-Equity 2.44
Debt-to-EBITDA -0.66
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -191.5
3-Year EPS without NRI Growth Rate -168.9
3-Year FCF Growth Rate -223.4

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 57.82
9-Day RSI 56.78
14-Day RSI 51.48
6-1 Month Momentum % -61.23
12-1 Month Momentum % -78.41

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.79
Quick Ratio 12.79
Cash Ratio 12.12

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -52.6
Name Current Vs Industry Vs History
ROE % -146.73
ROA % -72.83
ROIC % -1161.49
ROC (Joel Greenblatt) % -5084.48
ROCE % -79.53

Financials (Next Earnings Date:2022-08-10 Est.)

PHAT's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:PHAT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -4
Beta 0
Volatility % 58.38
14-Day RSI 51.48
14-Day ATR ($) 0.75618
20-Day SMA ($) 7.2565
12-1 Month Momentum % -78.41
52-Week Range ($) 6.095 - 37.17
Shares Outstanding (Mil) 39.07

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Phathom Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More